Funds to support clinical development of INX-315, the company’s lead Cyclin-Dependent Kinase 2 inhibitor Sid Subramony, Ph.D., of Boxer Capital…
SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:…
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it…
Partners with Award-Winning Director Maya Albanese “Patch and Play” introduces the features of the Twirla (levonorgestrel and ethinyl estradiol) transdermal…
CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that…
EB-101 pivotal phase 3 VIITAL™ study in RDEB achieves target enrollment; top-line data expected in third quarter of 2022; gained…
Identification and elimination of $7.5 million of annualized run-rate costs, focusing on future growth and sustainable profitabilityCost optimization activities will…
Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show…
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX ‐ XLY) (OTCQX: CBWTF) ("Auxly" or the "Company"),…
BETHLEHEM, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home…